Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 4 | 6 | +0,59 % | ||
| DISC MEDICINE | 3 | 7 | -0,57 % | ||
| VERTEX PHARMACEUTICALS | 3 | 5 | +0,41 % | ||
| NURIX THERAPEUTICS | 3 | 4 | +0,44 % | ||
| IDEAYA BIOSCIENCES | 3 | 3 | -1,29 % | ||
| VIATRIS | 3 | 2 | +0,32 % | ||
| BIONTECH | 2 | 13 | +0,06 % | ||
| ORIC PHARMACEUTICALS | 2 | 2 | +6,88 % | ||
| OCULAR THERAPEUTIX | 2 | 1 | -1,67 % | ||
| ADAPTIVE BIOTECHNOLOGIES | 2 | - | +2,73 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:30 | Wochenend-Update: Biontech-Aktie im Fokus - was Anleger jetzt wissen müssen! | Hebelschein-Spekulant | |||
| 15:54 | Nurix reports 83% response rate for bexobrutideg in CLL patients | 1 | Investing.com | ||
| 15:46 | Nurix: Bexobrutideg erzielt 83 % Ansprechrate bei Leukämie-Patienten | 2 | Investing.com Deutsch | ||
| 15:36 | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | 277 | AFX News | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen | |
| 15:36 | Cogent Biosciences, Inc.: Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) | 2 | GlobeNewswire (USA) | ||
| 15:36 | Genmab A/S: Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) | 4 | GlobeNewswire (USA) | ||
| 15:36 | Nurix Therapeutics, Inc.: Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American ... | 1 | GlobeNewswire (USA) | ||
| 15:06 | Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11 | 258 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced new data from pivotal studies of CASGEVY (exagamglogene autotemcel), demonstrating the transformative... ► Artikel lesen | |
| 14:36 | Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 14:22 | Beam Therapeutics: Positive Studiendaten zur Sichelzelltherapie treiben Aktie an | 6 | Investing.com Deutsch | ||
| 14:22 | Disc Medicine meldet positive Studiendaten zu Anämie-Medikament DISC-0974 | 2 | Investing.com Deutsch | ||
| 14:18 | Disc Medicine reports positive data from DISC-0974 anemia trial | 1 | Investing.com | ||
| 14:12 | Arvinas Inc.: Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition | 4 | GlobeNewswire (USA) | ||
| 14:06 | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 14:06 | Disc Medicine Inc: Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 13:50 | Samstag-Meldung zu BIONTECH SE ADR: Jetzt wird's brisant! | 14 | Maximilian Berger | ||
| 13:06 | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions | 327 | Business Wire | - Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy... ► Artikel lesen | |
| 02:06 | ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 | 1 | GlobeNewswire (USA) | ||
| Fr | Kymera rises on upcoming data release for eczema asset KT-621 | 1 | Seeking Alpha | ||
| Fr | Ocular Therapeutix plant Zulassungsantrag für AXPAXLI auf Basis von Phase-3-Daten | 12 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .